BRISBANE: CareDx Inc. has agreed to acquire precision oncology diagnostics company Naveris for up to $260 million, expanding its testing services beyond transplant medicine into cancer monitoring. The deal includes $160 million in upfront cash and up to $100 million tied to revenue milestones, the companies said. The transaction is expected to close in…
AUSTIN – Natera Inc has acquired Foresight Diagnostics, a move that expands its portfolio of tests that detect trace amounts of cancer left after treatment, in a deal worth up to $450 million. The all-stock transaction includes a $275 million upfront payment and up to $175 million in earnouts tied to future revenue and…
SYDNEY: TrivarX Ltd (ASX: TRI) said on Thursday it will acquire the intellectual property for Stabl-Im™, a novel brain cancer imaging technology, from Australian biotech firm Nucleics Pty Ltd, in a deal aimed at expanding its diagnostics portfolio into neuro-oncology. The Perth and Minneapolis-based company has entered a binding option agreement to acquire 100%…
CHICAGO: Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence-driven precision medicine, announced Friday it has acquired Paige, a digital pathology company known for pioneering FDA-cleared AI applications in cancer detection. The $81.25 million deal, primarily paid in Tempus common stock, positions Tempus to expand its oncology-focused dataset and technical capabilities. Founded in…
LONDON: Diaceutics PLC (AIM: DXRX), a technology provider for pharmaceutical and biotech companies, announced strong first-half revenue growth driven by increased demand for its precision medicine commercialization services. Revenue rose 22% on a constant currency basis to £14.6 million ($18.9 million) in H1 2025, marking a three-year compound annual growth rate of 25%. Recurring…
NEW YORK: Renalytix AI plc announced a collaboration with AstraZeneca to develop and launch precision medicine strategies for cardiovascular, renal and metabolic diseases. The first stage in the collaboration will use KidneyIntelX, an artificial intelligence-enabled in vitro diagnostic platform, to examine further improving outcomes for patients with chronic kidney disease (CKD) and its complications,…